November 15, 2019
L-Carnitine Supplements For Treating Chronic Heart Failure

L-Carnitine Supplements For Treating Chronic Heart Failure

Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

The dietary supplement L-Carnitine has been shown to be helpful for improving symptoms of chronic heart failure in studies.

L-Carnitine is an amino acid derivative that plays a vital role in energy and fatty acid metabolism by transporting fatty acids into the mitochondria matrix.

L-Carnitine can be synthesized endogenously in the body using the amino acids lysine and methionine.

However, individuals with genetic issues or those following vegan diets may be unable to produce enough or obtain enough carnitine from the diet.

Vegan diets are methionine restricted, often low in lysine and do not provide carnitine directly.  Red meat such as beef and lamb are considered to be the best dietary sources of carnitine.

Heart failure often referred to as “congestive heart failure” is a serious progressive condition where the heart is unable to pump sufficiently to maintain blood flow to meet the body’s needs.

Many nutraceuticals have now been shown to be of potential benefit in treating and improving symptoms of chronic heart failure including Coenzyme Q10, Taurine, D-Ribose and of course L-Carnitine.

L-Carnitine For Treating Chronic Heart Failure

A fairly recent meta-analysis of randomized controlled trials published in 2017 evaluated the effects of L-Carnitine treatment in chronic heart failure(CHF) patients.

Seventeen randomized controlled trials(RCTs) with 1625 CHF patients were included in this analysis.

L-carnitine treatment in CHF was associated with considerable improvement in overall efficacy (OR = 3.47, ), left ventricular ejection fraction (LVEF) (WMD: 4.14%, ), strike volume (SV) (WMD: 8.21 ml, ), cardiac output (CO) (WMD: 0.88 L/min, ), and E/A (WMD: 0.23, ).

Moreover, treatment with L-C also resulted in significant decrease in serum levels of BNP (WMD: −124.60 pg/ml, ), serum levels of NT-proBNP (WMD: −510.36 pg/ml, ), LVESD (WMD: −4.06 mm, ), LVEDD (WMD: −4.79 mm, ), and LVESV (WMD: −20.16 ml, 95% CI: −35.65 to −4.67, ).

However, there were no significant differences in all-cause mortality, 6-minute walk, and adverse events between L-C and control groups.

Conclusions:

L-carnitine treatment is effective for CHF patients in improving clinical symptoms and cardiac functions, decreasing serum levels of BNP and NT-proBNP. And it has a good tolerance. [1]

References

[1] Efficacy and Safety of L-Carnitine Treatment for Chronic Heart Failure: A Meta-Analysis of Randomized Controlled Trials

https://www.hindawi.com/journals/bmri/2017/6274854/

The information in this article has not been evaluated by the FDA and should not be used to diagnose, cure or treat any disease, implied or otherwise.

Leave a Reply

Your email address will not be published. Required fields are marked *